Payment overview · 2025
General Payments
$989.81
34 reported records · 15 companies
Healthcare provider profile · identity verified
Jully M Sanchez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1689959264
Verified facts
What the public records show
CMS Open Payments records show Jully M Sanchez, MD received $989.81 in general payments during 2025 across 34 reported records.
Novo Nordisk Inc accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $348.97 | 35.3% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $162.51 | 16.4% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $124.70 | 12.6% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $93.46 | 9.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $72.97 | 7.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.93 | 2.9% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $21.65 | 2.2% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $20.16 | 2.0% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.86 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.91 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.34 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.68 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.95 | 1.5% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $14.38 | 1.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.34 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $989.81 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $269.13 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $162.51 | 5 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $124.70 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $124.70 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $93.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $72.97 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.41 | 3 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $14.38 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 200 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
200 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 898 | 293 |
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 160 |
| Lisinopril | Lisinopril | 437 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 118 |
| Losartan Potassium | Losartan Potassium | 397 | 122 |
| Gabapentin | Gabapentin | 381 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 331 | 107 |
| Alendronate Sodium | Alendronate Sodium | 296 | 107 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 285 | 49 |
| Metformin Hcl | Metformin Hcl | 280 | 105 |
| Jardiance | Empagliflozin | 258 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 258 | 98 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 239 | 83 |
| Montelukast Sodium | Montelukast Sodium | 231 | 78 |
| Ozempic | Semaglutide | 200 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 74 |
| Glipizide Er | Glipizide | 184 | 59 |
| Tramadol Hcl | Tramadol Hcl | 181 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 57 |
| Celecoxib | Celecoxib | 166 | 75 |
| Omeprazole | Omeprazole | 165 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 164 | 68 |
| Metformin Hcl Er | Metformin Hcl | 161 | 51 |
| Telmisartan | Telmisartan | 161 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 52 |
| Furosemide | Furosemide | 149 | 61 |
| Carvedilol | Carvedilol | 146 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 47 |
| Januvia | Sitagliptin Phosphate | 122 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 36 |
| Famotidine | Famotidine | 115 | 40 |
| Ezetimibe | Ezetimibe | 108 | 43 |
| Nifedipine Er | Nifedipine | 108 | 38 |
| Sertraline Hcl | Sertraline Hcl | 107 | 37 |
| Mounjaro | Tirzepatide | 101 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 42 |
| Spironolactone | Spironolactone | 92 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 26 |
| Farxiga | Dapagliflozin Propanediol | 89 | 24 |
| Trazodone Hcl | Trazodone Hcl | 87 | 41 |
| Myrbetriq | Mirabegron | 78 | 24 |
| Enalapril Maleate | Enalapril Maleate | 77 | 26 |
| Buspirone Hcl | Buspirone Hcl | 76 | 25 |
| Donepezil Hcl | Donepezil Hcl | 75 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 74 | 20 |
| Clonazepam | Clonazepam | 74 | 15 |
| Glimepiride | Glimepiride | 72 | 21 |
| Potassium Chloride | Potassium Chloride | 72 | 27 |
| Trulicity | Dulaglutide | 69 | 20 |
| Bupropion Xl | Bupropion Hcl | 68 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 25 |
| Mirtazapine | Mirtazapine | 66 | 22 |
| Pregabalin | Pregabalin | 66 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 62 | 24 |
| Ibuprofen | Ibuprofen | 60 | 29 |
| Eliquis | Apixaban | 55 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 51 | 23 |
| Alprazolam | Alprazolam | 48 | suppressed |
| Simvastatin | Simvastatin | 47 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 13 |
| Finasteride | Finasteride | 43 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Tradjenta | Linagliptin | 42 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 15 |
| Meclizine Hcl | Meclizine Hcl | 39 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 25 |
| Allopurinol | Allopurinol | 37 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 18 |
| Fluconazole | Fluconazole | 36 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 12 |
| Methocarbamol | Methocarbamol | 32 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 11 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 23 |
| Constulose | Lactulose | 28 | 12 |
| Temazepam | Temazepam | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | 11 |
| Lyrica | Pregabalin | 24 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | suppressed |
| Xifaxan | Rifaximin | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 17 |
| Nystatin | Nystatin | 23 | 12 |
| Valsartan | Valsartan | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Linzess | Linaclotide | 22 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 17 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 20 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 19 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Clotrimazole | Clotrimazole | 18 | 13 |
| Acyclovir | Acyclovir | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Baclofen | Baclofen | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $989.81 · 34 records | Novo Nordisk Inc | ABRYSVO, AURYON LASER SYSTEM 100-120 VAC, Barostim Neo System, CAPVAXIVE, COMIRNATY, CRYSVITA, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, Kerendia, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, ULTOMIRIS, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error